Literature DB >> 565520

Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.

J M Vigouret, H R Bürki, A L Jaton, P E Züger, D M Loew.   

Abstract

Neurochemical and neuropharmacological investigations with four ergot derivatives reveal differential pharmacodynamic effects of these compounds. Bromocriptine and CM 29-712 showed actions typical of postsynaptic dopamine receptor stimulants, in particular in the extrapyramidal system. CM 29-712 proved to be more potent than bromocriptine, with an early onset of action. CF 25-397 and dihydroergotoxine, while not showing all actions typical of central dopamine agonists, appeared to exert some of their effects by means of a stimulation of central serotoninergic sites. In the rat sleep-wakefulness cycles and in reserpine-induced ponto-geniculooccipital waves in the cat, they mimicked the effects of 5-hydroxytryptophan. In the latter test, CF 25-397 proved to be particularly potent. In addition, bromocriptine, dihydroergotoxine and CM 29-712 showed neurochemical effects consistent with central alpha-adrenergic blockade or an enhanced impulse flow in central noradrenergic neurons.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565520     DOI: 10.1159/000136817

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  12 in total

1.  SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; K McAllister; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.

Authors:  H R Bürki; H Asper; W Ruch; P E Züger
Journal:  Psychopharmacology (Berl)       Date:  1978-05-31       Impact factor: 4.530

3.  A new semisynthetic ergot peptide alkaloid: DCN 203-922.

Authors:  R K Giger; H R Loosli; M D Walkinshaw; B J Clark; J M Vigouret
Journal:  Experientia       Date:  1987-10-15

4.  Differential behavioral and biochemical effects of four dopaminergic agonists.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions.

Authors:  R Markstein
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

6.  Inhibition of reserpine-induced PGO waves in the cat by ergot derivatives.

Authors:  P E Züger; J M Vigouret; D M Loew
Journal:  Experientia       Date:  1978-05-15

7.  The functional role of the noradrenergic neurons in the thermoregulatory circuits in mice.

Authors:  E L Schelkunov; O G Andreeva; K F Korovin; M N Ostroumova
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  Effect of dihydroergotoxine on the susceptibility of rats to convulsions produced by different convulsant agents.

Authors:  D Pericić; H Manev
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

10.  Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.

Authors:  E Flückiger; U Briner; H R Bürki; P Marbach; H R Wagner; W Doepfner
Journal:  Experientia       Date:  1979-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.